MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.leukres.2022.107005

Медицинская библиотека · Leukemia research · 2022

Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease.

Lebon Delphine, Dujardin Adèle, Caulier Alexis, Joris Magalie, Charbonnier Amandine, Gruson Bérengère, Quint Marine, Castelain Sandrine, François Catherine, Lacassagne Marie-Noëlle, Guillaume Nicolas, Marolleau Jean-Pierre, Morel Pierre

СтатьяПеревод в очереди

Аннотация

OBJECTIVES

Steroid-refractory graft-versus-host disease (SR-GVHD) is a challenging complication of allogeneic hematopoietic stem cell transplantation, and leads to high morbidity and mortality rates. The orally administered, selective Janus-associated kinase 1/2 inhibitor ruxolitinib gives overall response rates (ORR) of more than 70 % in acute and chronic SR-GVHD. However, several studies have highlighted an elevated risk of cytomegalovirus (CMV) reactivation in patients with ruxolitinib-treated SR-GVHD.

METHODS

We therefore analyzed risk of CMV and Epstein-Barr virus (EBV) primary infection or reactivation in 57 patients with ruxolitinib-treated GVHD, while taking account of the competing risk (CR) of death prior to the first reactivation.

RESULTS

Initiation of ruxolitinib treatment was a significant adverse prognostic factor for the CR of first CMV reactivation (hazard ratio (HR)= 1.747, 95 % confidence interval (CI): 1.33-2.92, p < 0.0001) and first EBV reactivation (HR=2.657, 95 % CI: 1.82-3.87, p < 0.0001) during GVHD. In our cohort of ruxolitinib-treated patients, the ORR (48 % and 58 % for acute and chronic GVHD, respectively) and the toxicity profile (haematological adverse events in 29.8 % of the patients) were similar to the literature values.

CONCLUSION

Given ruxolitinib's efficacy in SR-GVHD, use of this drug should not be limited by the fear of viral reactivation; however, our present results emphasize the importance of monitoring the viral load.

Для цитирования: Lebon Delphine, Dujardin Adèle, Caulier Alexis, Joris Magalie, Charbonnier Amandine, Gruson Bérengère, Quint Marine, Castelain Sandrine, François Catherine, Lacassagne Marie-Noëlle, Guillaume Nicolas, Marolleau Jean-Pierre, Morel Pierre. Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease.. Leukemia research. 2022. DOI: 10.1016/j.leukres.2022.107005.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.